Management of severe osteoporosis.
Miller PD.
Expert Opin Pharmacother. 2016;17(4):473-88. doi: 10.1517/14656566.2016.1124856. Epub 2015 Dec 23.
Current Status of the Diagnosis and Management of Osteoporosis.
Aibar-Almazán A, Voltes-Martínez A, Castellote-Caballero Y, Afanador-Restrepo DF, Carcelén-Fraile MDC, López-Ruiz E.
Int J Mol Sci. 2022 Aug 21;23(16):9465. doi: 10.3390/ijms23169465.
Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2. Epub 2017 Nov 9.
Osteoporosis and periodontal diseases - An update on their association and mechanistic links.
Yu B, Wang CY.
Periodontol 2000. 2022 Jun;89(1):99-113. doi: 10.1111/prd.12422. Epub 2022 Mar 4.
Long-term consequences of osteoporosis therapy with bisphosphonates.
Gehrke B, Alves Coelho MC, Brasil d'Alva C, Madeira M.
Arch Endocrinol Metab. 2023 Nov 10;68:e220334. doi: 10.20945/2359-4292-2022-0334.
Post-menopausal Osteoporosis and Probiotics.
Huidrom S, Beg MA, Masood T.
Curr Drug Targets. 2021;22(7):816-822. doi: 10.2174/1389450121666201027124947.
Osteoporosis. Definition and clinical presentation.
Glaser DL, Kaplan FS.
Spine (Phila Pa 1976). 1997 Dec 15;22(24 Suppl):12S-16S. doi: 10.1097/00007632-199712151-00003.
Quality of life in postmenopausal women with osteoporosis: a systematic review and meta-analysis.
Gao S, Zhao Y.
Qual Life Res. 2023 Jun;32(6):1551-1565. doi: 10.1007/s11136-022-03281-1. Epub 2022 Nov 16.
Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
Shane E, Shiau S, Recker RR, Lappe JM, Agarwal S, Kamanda-Kosseh M, Bucovsky M, Stubby J, Cohen A.
J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1528-e1540. doi: 10.1210/clinem/dgab850.
Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbini CAF, Wang Z, Oates MK, Recknor C, Libanati C.
J Bone Miner Res. 2021 Nov;36(11):2139-2152. doi: 10.1002/jbmr.4409. Epub 2021 Aug 10.
